Pdt Partners, LLC Next Cure, Inc. Transaction History

Pdt Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $131,003 - $209,145	-22,983 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $258,687 - $307,815	-38,381 Reduced 62.55%	22,983 $155,000
Q2 2021 Aug 16, 2021	SELL	$7.6 - $10.28 $42,240 - $57,136	-5,558 Reduced 8.31%	61,364 $493,000
Q1 2021 May 17, 2021	SELL	$9.81 - $13.88 $264,242 - $373,871	-26,936 Reduced 28.7%	66,922 $670,000
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $1.27 Million - $1.66 Million	-133,755 Reduced 58.76%	93,858 $1.02 Million

Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $1.75 Million - $4.56 Million	215,243 Added 1740.04%	227,613 $2 Million
Q2 2020 Aug 14, 2020	BUY	$21.19 - $40.2 $99,508 - $188,779	4,696 Added 61.19%	12,370 $265,000
Q1 2020 May 15, 2020	BUY	$32.32 - $58.37 $248,023 - $447,931	7,674 New	7,674 $284,000

16.1M

10.5K

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $41.6M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.